Clinical Trials (Phase IV)

Found 3,296 articles

• Real-World Study Shows Merck's ZEPATIER (Elbasvir and Grazoprevir) Resulted in High Rates of Sustained Virologic Response in Patients With Chronic Hepatitis C Infection Who Have Chronic Kidney Disease

  10/23/2017

  These findings will be presented today at The Liver Meeting 2017 taking place in Washington, D.C.

• Angle PLC: Researchers Develop Parsortix-Based Process to Efficiently Harvest Cancer Cells From Bone Marrow

  10/23/2017

  ANGLE plc., a world-leading liquid biopsy company, today announces that the Center for Women's Health Tuebingen, Germany, has presented the first report on a successful establishment of a protocol for detecting disseminated tumour cells (DTCs) using cancer patient bone marrow with the Parsortix system.

• W. L. Gore & Associates, Inc. Release: Physicians Report Early Successes Across Multiple Applications in First-in-Human Uses of GORE® SYNECOR Preperitoneal Biomaterial Hernia Repair Device

  10/23/2017

  Physicians among the first to use the GORE SYNECOR Preperitoneal Biomaterial, a unique hybrid device for hernia repair, are reporting positive experiences in using the device in a range of applications, according to W. L. Gore & Associates (Gore).

• Spineology Initiates Post-Market Lateral Interbody Fusion Study Using Novel Implant Design

  10/23/2017

  Spineology Inc., the innovator in anatomy-conserving spine surgery, has announced the initiation of a prospective, post-market lateral interbody fusion study designed to evaluate patient outcomes using its FDA-cleared Duo Lumbar Interbody Fusion System.

• GeneSight Shown to Statistically Significantly Improve Generalized Anxiety Disorder Treatment Response and Decrease Benzodiazepine Use

  10/20/2017

  Assurex Health, a wholly-owned subsidiary of Myriad Genetics, today announced new positive results for the GeneSight test in patients with Generalized Anxiety Disorder (GAD).

• New Study Comparing Effectiveness of Alkermes' Extended-Release Naltrexone to Buprenorphine-Naloxone for Opioid Dependence Published in JAMA Psychiatry

  10/19/2017

  Results were published this week in the Journal of the American Medical Association Psychiatry.

• OncoSNIPE Artificial Intelligence Project Officially Launched

  10/19/2017

  Oncodesign, a biopharmaceutical group specialized in precision medicine, and UNICANCER present the details of the OncoSNIPE project, which aims to develop and apply artificial intelligence techniques to cancer research.

• BioElectronics Announces Independent Back Pain Clinical Study Pulsed Neuromodulation Therapy (ActiPatch) for Chronic Musculoskeletal Lower Back Pain

  10/19/2017

  BioElectronics is pleased to announce the commencement of a clinical study investigating the efficacy of ActiPatch in treating chronic musculoskeletal lower back pain.

• Novartis Drug Revolade Shows Long-Term Disease Control for Chronic/Persistent Immune Thrombocytopenia (ITP)

  10/18/2017

  The long term study results were published online in Blood.

• iSTAR Medical Completes Enrollment Of First-In-Human Migs Trial

  10/17/2017

  iSTAR Medical announced today the completion of enrollment in their first-in-human (FIH) micro-invasive glaucoma surgery (MIGS) trial for the MINIjectTM device.

• Theravance Biopharma Reports Positive New Data From Multiple Studies Of VIBATIV (Telavancin) At IDWeek 2017

  10/9/2017

• Mallinckrodt Will Conduct Phase IV Trial Of H.P. Acthar Gel (Repository Corticotropin Injection) For Symptomatic Sarcoidosis

  10/9/2017

• Amgen Release: First Randomized Study To Evaluate IMLYGIC (Talimogene Laherparepvec), An Oncolytic Viral Therapy, In Combination With A Checkpoint Inhibitor Published In The Journal Of Clinical Oncology

  10/6/2017

• Phase III Study Using 22nd Century Group, Inc.’s SPECTRUM Research Cigarettes Demonstrates Immediate Reduction To Very Low Nicotine Is Most Likely To Lead To Less Harm

  10/6/2017

• The Medicines Company To Present New Data From TANGO II Study Of VABOMERE (Meropenem And Vaborbactam) At IDWeek 2017

  10/5/2017

• 

  BioPharm Executive: From the Bench to the Clinic

  9/27/2017

  Alnylam's victory with Patisiran in familial amyloid polyneuropathy (FAP) is significant for more than just the company and its patients.

• Agena Biosciences Release: Highly Sensitive Assessment Of Common Somatic Mutations In Pulmonary Non-Small Cell Carcinoma With The MassARRAY System

  9/27/2017

• BioTime Announces Positive Secondary And Additional Positive Long-Term Data From The Renevia Pivotal Trial

  9/26/2017

• Novartis AG Release: New Analysis Shows Entresto Improved Physical And Social Activity In Patients With HFrEF

  9/19/2017

• Champions Oncology Announces Publication Highlighting Clinical Correlation Between Patient-Derived Xenograft (PDX) Model Responses And Patient Responses To Oncology Therapies

  9/18/2017